ILMN Stock Price Today (June 2026) — Illumina, Inc. Analysis & Key Metrics 2026-06-16
Illumina, Inc. (ILMN) is trading at $164.28, down 1.56% today (as of June 2026). The stock continues to show sustained strength above key moving averages, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $143.83 (-12.4% upside).
- Volatility remains elevated (39.52% annualized), implying wide price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (4.80% YoY) alongside significant competitive pressures.
ILMN Stock Analysis: Key Metrics & Valuation (June 2026)
Concise, actionable data for investors
Illumina, Inc. - Historical Price & Volume
Market Cap
Enterprise Value: $25.30B
P/E Ratio
Forward P/E: 26.69
Revenue Growth
Year over Year
Analyst Target
+-12.4% upside potential
Key Investor Questions About ILMN
What investors need to know before buying
Based on current market data, ILMN presents a neutral technical setup with caution warranted fundamentals.
- Technicals say: Neutral (RSI 59.34)
- Fundamentals say: Caution warranted (high leverage concerns)
ILMN's growth trajectory depends on its ability to expand within the Diagnostics & Research sector while managing margin pressures.
- Future growth will depend on performance in core Diagnostics & Research operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for ILMN investors include debt exposure and competitive dynamics in the Diagnostics & Research industry.
- $2.54B in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Diagnostics & Research.
52-Week Trading Range
Over the past year, ILMN stock traded between $85.00 and $177.22—recovering meaningfully from lows and currently near the higher end. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 39.52% annualized volatility and β=1.03, the stock exhibits moderate correlation to market moves—making ILMN suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional backing, but elevated short interest signals a potential battleground stock.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
1 Unpopular Stock That Deserves Some Love and 2 Facing Challenges
Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cordial corporate relationships often trumps delivering the hard truth.
Stocks Settle Sharply Lower on Escalating Middle East Tensions
The S&P 500 Index ($SPX ) (SPY ) on Wednesday closed down -1.62%, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed down -1.87%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -1.98%. June E-mini S&P futures (ESM26 ) fell -1.62%, and June E-mini Nasdaq futures...
Illumina upgraded to overweight at JPMorgan on clinical demand outlook
Investing.com -- Illumina received a bullish rating upgrade from JPMorgan, which raised its recommendation to Overweight from Neutral and lifted its December 2026 price target to $185 from $125, citing growing confidence in the DNA sequencing company's ability to sustain strong growth despite increasing competition.
Stocks Resume Decline as Chipmakers and AI Companies Fall
The S&P 500 Index ($SPX ) (SPY ) today is down -0.61%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is down -0.88%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.80%. June E-mini S&P futures (ESM26 ) are down -0.71%, and June E-mini Nasdaq futures...
Stocks Fall on Weakness in Tech and Trucking Companies
The S&P 500 Index ($SPX ) (SPY ) today is down -0.28%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is down -0.38%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.28%. June E-mini S&P futures (ESM26 ) are down -0.25%, and June E-mini Nasdaq futures...
Nike downgraded, Oscar Health upgraded: Wall Street's top analyst calls
Nike downgraded, Oscar Health upgraded: Wall Street's top analyst calls
Nasdaq Futures Plunge as Tech Selloff Deepens, U.S. Inflation Data in Focus
June Nasdaq 100 E-Mini futures (NQM26) are down -1.61% this morning as investors continued to trim exposure to the technology sector, with the focus now turning to key U.S. inflation data.
Samsung Electronics invests $175 million in Element Biosciences' Series E funding round
June 9 (Reuters) - Privately held Element Biosciences said on Tuesday it had raised funds in an upsized Series E round, including $175 million from longtime investor Samsung Electronics, to expand
Samsung Elec invests $175 million to become top shareholder in US genetics firm
Privately held Element Biosciences said on Tuesday it had raised funds, including $175 million from longtime investor Samsung Electronics, to expand commercialisation of its genetic testing and research products. The San Diego-based company did not disclose the total size of the upsized Series E funding round, or its valuation. Samsung said in a statement that the investment would make it the largest shareholder in Element and deepen strategic cooperation between the two firms.
Illumina (ILMN) Valuation Check After New Oncology Collaborations And MRD Research Launch
Event driven focus on Illumina stock Illumina (ILMN) has drawn fresh attention after announcing a collaboration with Integrated DNA Technologies, the fireflyGO automation platform with SPT Labtech, and a new whole-genome-based MRD research kit for oncology. See our latest analysis for Illumina. These oncology focused launches come after a strong run in the stock, with Illumina’s share price up 14.41% over 30 days and 30.61% over 90 days, while the 1 year total shareholder return of 96.37%...
Frequently Asked Questions
Common investor questions about Illumina, Inc.
Illumina, Inc. (ILMN) is currently trading at $164.28. The RSI (14-day) is at 59.3, indicating neutral territory. Wall Street analysts have a consensus "buy" recommendation. The mean analyst price target of $143.83 implies 12.4% downside from current levels. Volatility is moderate at 39.5% annualized, meaning price movements are relatively contained. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Illumina, Inc. (ILMN): The trailing P/E ratio is 29.87, which is in line with broader market averages. The forward P/E is 26.69, lower than the trailing P/E, suggesting analysts expect earnings improvement. The PEG ratio is 2.85, above 2.0, suggesting the stock may be overvalued relative to its expected growth. Price-to-Book is 9.33. Price-to-Sales is 5.66. Valuation should be compared to Diagnostics & Research industry peers for context, as different sectors trade at different multiples.
Based on 18 analysts covering ILMN, the consensus price target is $143.83. This represents a 12.4% downside from the current price of $164.28. The range spans from a low target of $95.00 to a high target of $180.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Illumina, Inc. (ILMN) does not currently pay a regular dividend. The company may be reinvesting profits into growth initiatives, or may not yet be profitable enough to distribute earnings to shareholders.
Key risks for Illumina, Inc. (ILMN) investors include: 1. Moderate volatility (39.5% annualized)—price swings are notable. 2. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 3. Diagnostics & Research sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Illumina, Inc.'s (ILMN) current debt and financial health profile: Total debt stands at $2.54B. The debt-to-equity ratio is 95.07, which is elevated and warrants monitoring, especially in a rising interest rate environment. The current ratio is 1.75, indicating strong short-term liquidity. The quick ratio is 1.23. The company holds $1.16B in cash and equivalents. Free cash flow is positive at $845.63M, providing a cushion for debt servicing and shareholder returns.